NCT06485401View on ClinicalTrials.gov

To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

June 21, 2024

Study Completion Date

June 21, 2024

Conditions

Influenza Type AInfluenza Type B

Interventions

DRUG

ADC189

45 mg per tablet, oral administration, single dose.

Trial Locations (1)

Unknown

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

Jiaxing AnDiCon Biotech Co.,Ltd

INDUSTRY

NCT06485401 - To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects | Biotech Hunter | Biotech Hunter